Observational studyMedicine2025
Clinical utility of ultrasound in the assessment of sarcopenia in cancer patients: A cross-sectional study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia, defined as the loss of muscle mass accompanied by reduced strength and/or physical performance, is associated with numerous health risks, including falls, complications, prolonged hospitalization, and increased mortality. In cancer patients, sarcopenia is not only age-related but also aggravated by tumor-induced catabolism and treatment-related effects. Studies have shown that low muscle mass negatively impacts survival across various cancer types. Early detection of sarcopenia is therefore crucial to guide nutritional interventions and optimize treatment outcomes. To evaluate the clinical utility of ultrasound in the assessment of sarcopenia among cancer patients in Vietnam. This cross-sectional study was conducted on 224 cancer patients at Ho Chi Minh City Oncology Hospital from January to April 2024. All patients underwent computed tomography scans at the level of the 3rd lumbar vertebra, and muscle ultrasound assessments were performed on 2 lower limb muscles: the tibialis anterior and gastrocnemius muscles. Sarcopenia was diagnosed based on the 2019 criteria of the Asian Working Group for Sarcopenia. The prevalence of sarcopenia in the study population was 49.1%. Ultrasound measurements showed moderate diagnostic accuracy: the area under the receiver operating characteristic curve was 0.71 for the tibialis anterior muscle and 0.70 for the gastrocnemius muscle. For the tibialis anterior muscle, the optimal cutoff point was < 2.4 cm in men (sensitivity: 64.3%, specificity: 85.7%) and < 2.2 cm in women (sensitivity: 58.5%, specificity: 81.3%). For the gastrocnemius, the cutoff was < 1.8 cm in both sexes (sensitivity: 57.5%, specificity: 71.9%). This study highlights the potential utility of muscle ultrasound (particularly of the tibialis anterior and gastrocnemius muscles) as a noninvasive, accessible tool for sarcopenia screening in cancer patients. Given the limitations of conventional methods in this population, integrating ultrasound into clinical protocols may enhance individualized care, support early interventions, and improve patient outcomes and quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.